09 Dec 2024
Our Life Sciences businesses work alongside healthcare practitioners to navigate a complex regulatory environment and deliver innovative, market-leading solutions that improve patient outcomes.
Lung carcinoma remains the most common cause of cancer death worldwide. Nearly 85% of lung cancers are non-small cell lung cancer. This is often diagnosed at an advanced and metastatic stage. As a result, the prognosis of patients with this type of lung cancer remains poor, with average five-year survival rates at ca. 16%.
Existing market-standard diagnostic methods meant that it could take over 18 days between tumour sampling and initiation of treatment.
Peter Soelberg
CEO, International Life Sciences
Our Life Sciences Australasia business, Abacus dx, has worked closely with an existing supplier to bring a new diagnostic technology to the Australasian market, which significantly reduces the time from biopsy to diagnosis, improving patient survival rates.
The fully automated test brought to market by Abacus dx delivers results within 2.5 hours, reducing the time between sample to treatment to one or two days. Requires under two minutes of ‘hands-on’ time, and it is significantly less invasive than existing testing methods.
The test also avoids the challenge of obtaining samples of sufficient size and quality, encountered with traditional testing, by requiring a significantly smaller sample.
Abacus dx has demonstrated its value to patients across Australia and New Zealand, its customers, and its supplier in bringing this product to market.
Laboratories and hospitals have assurance of a steady and reliable supply of reagents for this urgent and much needed test, and have access to ongoing support in the repair and maintenance of the testing platform.
In addition to providing suppliers with an efficient route to market, Abacus dx promotes the product nationally, publishing articles about the testing platform and engaging key opinion leaders and medical experts to raise awareness of faster testing at scientific and oncology conferences. All of these actions result in better outcomes for cancer patients.
Read the full announcement:
Our Life Sciences Sector